Levoftyal (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By inhibiting these targets, the drug prevents bacterial cell division, leading to rapid bacterial death and effective eradication of susceptible ocular pathogens.

The dosing regimen for Levoftyal is determined by the prescribing clinician based on the specific infection, severity, and patient factors. Healthcare professionals set the frequency and duration of eye‑drop administration in accordance with clinical guidelines.

Levoftyal’s pregnancy category is listed as unknown, and safety data are limited. Caution is advised when prescribing to pregnant or nursing women; the prescriber should weigh potential benefits against possible risks and consider alternative therapies if appropriate.

To request Levoftyal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Levoftyal belongs to the fluoroquinolone class, offering broad‑spectrum activity against Gram‑positive and Gram‑negative bacteria. Compared with older agents such as ciprofloxacin, levofloxacin provides enhanced potency and a lower risk of resistance development, while maintaining a similar safety profile for ocular use.

Levoftyal should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from direct light, moisture, and extreme temperatures to maintain stability. Do not freeze the solution, and keep the container tightly closed when not in use.

Levoftyal is applied directly to the affected eye(s) as prescribed. Typically, a few drops are instilled into the conjunctival sac, avoiding contact with the eyelid or lashes. Patients should wash their hands before and after administration and follow the dosing schedule provided by their eye‑care professional.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and corneal ulceration or perforation. Any signs of intense ocular pain, swelling, rash, or systemic symptoms should prompt immediate medical attention and discontinuation of the product.

Levoftyal is contraindicated in individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. It should also be avoided in patients with active corneal epithelial defects or severe ocular surface disease unless specifically directed by an ophthalmologist.